Recently, Howell and coworkers reported on the use of the CRISPR-Cas9 technique to individually knock out the human copper transporters CTR1 and CTR2 and the copper chaperones ATOX1 and CCS in human cancer cells (Bompiani et al., 2016). This evidence concerns the gene SLC31A1 and cancer.